Drug Trial Radar · NCT02346487
Prospective Study of Lopinavir Based ART for HIV Infected childreN Globally (LIVING Study)
Last checked: Nov 19, 2026Latest source record: May 20, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,003
Actual
Start
Sep 2015
Primary completion
May 14, 2019
Study completion May 14, 2019
Sponsor
- Lead sponsor
- Drugs for Neglected DiseasesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- UNITAID; French Development Agency
- First posted
- Jan 27, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will be carried out to provide supportive clinical data on the feasibility, efficacy, safety, and PK of LPV based therapies in routine treatment setting and will be based on the existing LPV/r pellets which already represent a clear advantage in comparison with the liquid formulation.
Conditions
- HIV
Interventions
LPV/RTV pellets and AZT/3TC or ABC/3TCDrug
Drug: LPV/r pellets 40/10 mg: orally taken twice a day. Dosage according to patient's weight: * Between 3 and 5.9kg: 2 capsules twice a day * Between 6 and 9.9kg: 3 capsules twice a day * Between 10 and 13.9kg: 4 capsules twice a day * Between 14 and 19.9kg: 5 capsules twice a day * Between 20 and 24.9kg: 6 capsules twice a day Drug: NRTIs (AZT/3TC 60/30mg tablet or ABC/3TC 60/30mg tablet). Dosage according to patient's weight: * Between 3 and 5.9kg: 1 tablet twice a day * Between 6 and 9.9kg: 1.5 tablets twice a day * Between 10 and 13.9kg: 2 tablets twice a day * Between 14 and 19.9kg: 2.5 tablets twice a day * Between 20 and 24.9kg: 3 tablets twice a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment effectiveness at 48 weeks based on a composite endpoint of: i) virologic response <1000 copies/ml ii) being alive and iii) on study drugTime frame: 48 weeks
Locations
11 sites in 3 countries. Site status is shown where the registry gives one.
AMPATH - Moi Teaching and Referral Hospital
Eldoret, Kenya
FACES Lumumba Clinic
Kisumu, Kenya
Gertrude's Children Hospital
Nairobi, Kenya
Kenyatta National Hospital
Nairobi, Kenya
Management and Development for Health(MDH) , at Temeke and Amana Hospitals
Dar es Salaam, Tanzania
Ifakara health Institute
Morogoro, Tanzania
Joint Clinical research Centre
Fort Portal, Uganda
Joint Clinical Research Centre
Gulu, Uganda
Baylor College of Medicine, Children's Foundation - Uganda
Kampala, Uganda
Joint Clinical research Centre
Kampala, Uganda
Epicentre Mbarara Research Centre
Mbarara, Uganda
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.